Porubsky Stefan, Federico Giuseppina, Müthing Johannes, Jennemann Richard, Gretz Norbert, Büttner Stefan, Obermüller Nicholas, Jung Oliver, Hauser Ingeborg A, Gröne Elisabeth, Geiger Helmut, Gröne Hermann-Josef, Betz Christoph
Department of Cellular and Molecular Pathology, German Cancer Research Centre, Heidelberg, Germany; Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.
J Pathol. 2014 Sep;234(1):120-33. doi: 10.1002/path.4388. Epub 2014 Jul 25.
The pathogenesis and therapy of Shigatoxin 2 (Stx2)-mediated kidney failure remain controversial. Our aim was to test whether, during an infection with Stx2-producing E. coli (STEC), Stx2 exerts direct effects on renal tubular epithelium and thereby possibly contributes to acute renal failure. Mice represent a suitable model because they, like humans, express the Stx2-receptor Gb3 in the tubular epithelium but, in contrast to humans, not in glomerular endothelia, and are thus free of glomerular thrombotic microangiopathy (TMA). In wild-type mice, Stx2 caused acute tubular dysfunction with consequent electrolyte disturbance, which was most likely the cause of death. Tubule-specific depletion of Gb3 protected the mice from acute renal failure. In vitro, Stx2 induced secretion of proinflammatory cytokines and apoptosis in human tubular epithelial cells, thus implicating a direct effect of Stx2 on the tubular epithelium. To correlate these results to human disease, kidney biopsies and outcome were analysed in patients with Stx2-associated kidney failure (n = 11, aged 22-44 years). The majority of kidney biopsies showed different stages of an ongoing TMA; however, no glomerular complement activation could be demonstrated. All biopsies, including those without TMA, showed severe acute tubular damage. Due to these findings, patients were treated with supportive therapy without complement-inhibiting antibodies (eculizumab) or immunoadsorption. Despite the severity of the initial disease [creatinine 6.34 (1.31-17.60) mg/dl, lactate dehydrogenase 1944 (753-2792) U/l, platelets 33 (19-124)/nl and haemoglobin 6.2 (5.2-7.8) g/dl; median (range)], all patients were discharged after 33 (range 19-43) days with no neurological symptoms and no dialysis requirement [creatinine 1.39 (range 0.84-2.86) mg/dl]. The creatinine decreased further to 0.90 (range 0.66-1.27) mg/dl after 24 months. Based on these data, one may surmise that acute tubular damage represents a separate pathophysiological mechanism, importantly contributing to Stx2-mediated acute kidney failure. Specifically in young adults, an excellent outcome can be achieved by supportive therapy only.
志贺毒素2(Stx2)介导的肾衰竭的发病机制和治疗方法仍存在争议。我们的目的是测试在感染产Stx2的大肠杆菌(STEC)期间,Stx2是否对肾小管上皮产生直接影响,从而可能导致急性肾衰竭。小鼠是一个合适的模型,因为它们与人类一样,在肾小管上皮中表达Stx2受体Gb3,但与人类不同的是,它们在肾小球内皮中不表达,因此没有肾小球血栓性微血管病(TMA)。在野生型小鼠中,Stx2导致急性肾小管功能障碍,进而引起电解质紊乱,这很可能是死亡原因。肾小管特异性缺失Gb3可保护小鼠免于急性肾衰竭。在体外,Stx2可诱导人肾小管上皮细胞分泌促炎细胞因子并引发凋亡,从而表明Stx2对肾小管上皮有直接影响。为了将这些结果与人类疾病相关联,我们分析了11例(年龄22 - 44岁)与Stx2相关的肾衰竭患者的肾活检结果和预后情况。大多数肾活检显示存在进行性TMA的不同阶段;然而,可以证明没有肾小球补体激活。所有活检,包括那些没有TMA的活检,均显示严重的急性肾小管损伤。基于这些发现,患者接受了支持性治疗,未使用补体抑制抗体(依库珠单抗)或免疫吸附。尽管初始疾病严重[肌酐6.34(1.31 - 17.60)mg/dl,乳酸脱氢酶1944(753 - 2792)U/l,血小板33(19 - 124)/nl,血红蛋白6.2(5.2 - 7.8)g/dl;中位数(范围)],但所有患者在33(范围19 - 43)天后均出院,无神经症状且无需透析[肌酐1.39(范围0.84 - 2.86)mg/dl]。24个月后肌酐进一步降至0.90(范围0.66 - 1.27)mg/dl。基于这些数据,可以推测急性肾小管损伤代表一种独立的病理生理机制,对Stx2介导的急性肾衰竭有重要影响。特别是对于年轻人,仅通过支持性治疗就能取得良好的预后。